AOD-9604: What Happened in the Weight-Loss Trials?

Looking at the AOD-9604 evidence

AOD-9604 is still advertised for fat loss, despite an unsuccessful human obesity trial and the end of that development programme in 2007. Here is what was tested, why the way it was given matters and what the safety reports can and cannot tell us.

AOD-9604 evidence guide: a man reading in a library, with The Care Pharmacy branding

What is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone that was developed as a possible obesity treatment. The idea was to investigate effects on fat metabolism without giving the full growth hormone molecule.

That research idea should not be confused with a demonstrated benefit. A compound can have an interesting proposed mechanism and still fail to produce worthwhile weight loss when tested in people.

You may see the name written as AOD9604, without a hyphen. It refers to the same research compound. It is not a GLP-1 medicine or another brand of semaglutide or tirzepatide.

The Care Pharmacy does not offer AOD-9604. The useful question for someone considering it is what the human trials found, rather than how confidently an online seller describes it.

What happened in the larger AOD-9604 trial?

In a February 2007 stock-exchange announcement, developer Metabolic Pharmaceuticals said its phase 2b obesity trial did not support continuing the programme for that condition.

The announcement reported 536 participants and a diet-and-exercise programme alongside AOD-9604 or placebo. Weight loss with the compound was not significantly greater than placebo at the main 12-week assessment or the 24-week assessment. The company stopped development for obesity.

This was a phase 2b trial. The company said it had been designed with conditions intended to help predict a phase 3 outcome. That does not make it a completed phase 3 trial.

The finding matters because this was a direct attempt to test the weight-loss claim in people. It is more relevant to that claim than a laboratory explanation of how the compound might affect fat cells.

A failed comparison does not prove that no individual could ever experience a change while taking it. It means the trial did not establish the benefit needed to support using it as an obesity treatment.

Why do some reports still sound positive?

Earlier, smaller studies produced findings that encouraged further work. The FDA’s scientific review of the AOD-9604 programme discusses that evidence and its limitations, including incomplete published details about methods and results.

Early findings are supposed to be tested in larger studies. If the later trial does not confirm a benefit, the earlier result should not be presented as though the later work never happened.

There is another common source of confusion: safety findings and effectiveness findings answer different questions. A study describing tolerability does not establish that a product causes meaningful weight loss.

Personal stories are different again. Someone may lose weight while changing their diet, activity or other medicines at the same time as taking a peptide. Their experience cannot show which change caused the result.

A fair account therefore needs to include the unsuccessful obesity trial, rather than select only the most encouraging earlier statement.

Were the AOD-9604 studies testing injections?

Not every study used the same route. The larger obesity trial used an oral treatment. Earlier work also included other routes. That detail matters when a website uses the research to promote an injection under the skin.

The FDA’s review found no human information for the proposed products injected under the skin or applied to it. It could not establish their effectiveness and safety from the available material.

Changing how a compound enters the body can change its effects and risks. You cannot take a result from an oral trial and assume an injection must work better, or use it to calculate an injection dose.

Nor does a failed oral trial provide permission to experiment with an injected version. A different route needs evidence of its own. Claims that the route explains away the negative result remain claims until properly tested.

There is no safe self-injection, mixing or dosing schedule to provide from this evidence. A seller’s instructions are not a substitute for clinical trials or an authorised prescription.

What does the safety research tell us?

A 2013 paper summarised safety findings from six studies. Its authors reported favourable tolerability and no detected anti-AOD-9604 antibodies in the participants selected for testing. The paper also disclosed links to the developer.

The safety findings relate to the products, ways of giving treatment, participants and follow-up in those six studies. They do not show that a product advertised online today is safe or that long-term use has been adequately assessed.

The later FDA review raised concerns about limited clinical information, peptide impurities and potential immune reactions. It also noted that the available reports did not always provide enough detail to assess whether reported serious events were caused by the compound.

That uncertainty should not be turned into either a reassurance that there are no risks or a claim that every reported illness was caused by AOD-9604.

For a person considering buying a product, the practical issue is that benefit has not been established and important safety questions remain. A laboratory certificate claiming purity cannot answer those clinical questions.

Can you get AOD-9604 from The Care Pharmacy?

No. We do not supply AOD-9604, and our weight-loss consultation does not provide it.

Online availability is not proof of UK medicine authorisation, quality or suitability. A product being called a peptide, supplement or research material does not establish that it is appropriate to use as a weight-loss medicine.

It is also important to distinguish countries and regulatory processes. A US discussion about ingredients for compounded products is not a UK prescribing recommendation. A scientific assessment of evidence is different from an approval to sell a medicine for a particular use.

If you have already used a product, tell a healthcare professional what it was, when you used it and whether you have symptoms. Keep the packaging or product information if possible. Do not add another peptide to try to improve the result or manage an unwanted effect.

What should you look for in weight-loss treatment?

Look for a proper assessment and a clear explanation of the available options. Treatment should be based on your health, current medicines and previous care, rather than on a promise that a particular compound targets stubborn fat.

The NHS guide to overweight and obesity explains support with eating, activity, medicines and specialist services. Prescription treatment is one possible part of care, where it is appropriate.

If you are considering private treatment, ask how follow-up works and what happens if you cannot tolerate a medicine. Check the ongoing cost and how repeat prescriptions are reviewed. These are practical questions a service should be able to answer before you start.

You can also explain what has been difficult so far, whether that is hunger, side effects from previous treatment or keeping up with appointments. The assessment should help identify a workable approach, rather than simply replace one online product with another.

Common questions about AOD-9604

Has it been tested in people?

Yes. The issue is not a complete absence of human research. The larger obesity trial did not establish significantly greater weight loss than placebo, and development for obesity stopped.

Was the unsuccessful trial phase 3?

The developer described it as phase 2b. Its design included conditions intended to inform whether to proceed to phase 3. Those are not the same thing.

Does a safety paper prove that it works?

No. Tolerability and effectiveness need separate assessment. A safety summary cannot establish a weight-loss benefit that the efficacy trial did not demonstrate.

Can your consultation prescribe it?

No. The Care Pharmacy does not offer AOD-9604. Our consultation assesses suitability for the prescription weight-loss treatments currently offered through our service.

Find out whether weight-loss treatment is suitable for you

If you would like help choosing a weight-loss treatment, complete our online consultation. Our prescriber will review your health and current medicines to assess whether treatment is suitable.

Start consultation

This guide gives general information. Ask a qualified healthcare professional about your own treatment.

Prescription medicines require a clinical assessment. The clinician may recommend a different treatment or an in-person appointment.

Clinical reviewer

Mohammed Ismail Lakhi, MPharm, is the Superintendent Pharmacist at The Care Pharmacy. He leads clinical governance and is registered with the General Pharmaceutical Council, registration number 2072815.

Medically reviewed by

Mohammed Lakhi

Superintendent Pharmacist

Muhammad Lahki
Mohammed Ismail Lakhi

MOTS-c: What Is Behind the Weight-Loss Claims?

Research into MOTS-c does not all answer the same question. This guide separates studies of the body’s own peptide from claims about taking it.

Read More

CJC-1295 and Ipamorelin: Do the Fat-Loss Claims Add Up?

CJC-1295 and ipamorelin are often discussed together. Evidence for each substance should not be confused with evidence for the combination.

Read More

Tesamorelin: Does the Evidence Support Weight-Loss Claims?

The clinical use of tesamorelin is often confused with general fat-loss claims. This guide explains the distinction and the limits of the evidence.

Read More

Wegovy on the NHS in Scotland: How to Check Your Options

Can you get Wegovy on the NHS in Scotland? See how advice differs for injections and tablets and what to ask your local health board.

Read More

Wegovy on the NHS in Wales: How Specialist Referrals Work

Can you get Wegovy on the NHS in Wales? Learn what Level 3 weight management means and how to ask your local health board about a referral.

Read More

Wegovy in Guildford: NHS Referrals and Local Support

Looking into Wegovy in Guildford? See how to ask about a specialist NHS referral and where to find local weight management support in Surrey.

Read More
icon
UK-Prescribing Pharmacists
icon
No GP Appointments Needed
icon
Fast & Discreet Delivery